Genesis Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2011; filed November 21, 2011. The filing identifies the issuer as Genesis Biopharma, Inc., not Iovance Biotherapeutics, Inc., as stated in the request metadata.
Business context
Genesis was a development-stage biopharmaceutical company with no revenue. It had shifted from a planned freight business to cancer therapeutics. In October 2011, after the quarter-end, it entered an NIH license for tumor-infiltrating lymphocyte (TIL) therapies, including its proposed Cōntego program for metastatic melanoma and other cancers. It also decided to discontinue its anti-CD55 antibody program.
Financial results and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2011 and 2010 | $0 in 2011 and 2010 |
| Operating expenses | $5.81 million in 2011; $0.17 million in 2010 | $17.03 million in 2011; $0.32 million in 2010 |
| Net loss | $5.82 million in 2011; $0.71 million in 2010 | $17.34 million in 2011; $0.87 million in 2010 |
| Net loss per share | $0.07 in 2011; $0.01 in 2010 | $0.23 in 2011; $0.01 in 2010 |
| Cash used in operating activities | $3.48 million for the first nine months of 2011, versus $0.25 million in 2010 |
At September 30, cash and cash equivalents were $0.91 million, with a further $2.32 million classified as restricted cash pending NIH license execution; those proceeds were released in October. Current assets were $3.30 million and current liabilities $9.13 million, including $6.29 million of derivative liabilities. Excluding derivative liabilities, management reported working capital of approximately $0.46 million. Stockholders’ equity was negative $5.69 million.
The July 2011 financing comprised $5.00 million face value of 7% senior unsecured convertible notes, due November 30, 2011, and warrants. At quarter-end, the notes’ carrying value was $2.60 million after $2.40 million of unamortized discount. The company reported $3.12 million of financing cash inflows in the first nine months, including net note proceeds and equity issuance.
Changes, unusual items, and outlook
- Compared with 2010, operating expenses and net losses rose sharply as the company expanded development and corporate activities. Nine-month expenses included substantial stock-based compensation and shares issued for services.
- Quarterly and nine-month results included non-cash note-discount amortization of $2.60 million and gains from changes in derivative fair value of $3.55 million and $3.24 million, respectively. Nine-month net loss also included approximately $10.25 million of compensation paid in shares or through stock transfers, and approximately $3.10 million of non-cash option and warrant fair-value expense.
- The five-year NIH/NCI research agreement requires $1.00 million annually in quarterly installments; the first $250,000 installment was paid in September. The subsequent NIH license required approximately $1.20 million in upfront fees and reimbursements, due in early December 2011, plus royalties and milestone payments that could total $36.30 million across all four indications if all milestones are achieved.
- A November 2011 Lonza letter of intent contemplated process development and manufacturing work and a $500,000 non-refundable reservation fee, subject to stated exceptions. A definitive long-term agreement was not assured.
- Management said available resources, even assuming note conversion or a maturity extension, would fund operations only through approximately mid-March 2012. It estimated more than $35 million in spending over the next 12 months to develop Cōntego and meet NIH-related plans, and said substantial new financing was needed. No financing or strategic-partner commitments were in place; failure to raise funds could force curtailment or termination of activities.
- Management lacked funds to repay the $5.00 million notes at stated maturity and was seeking an extension to December 31, 2011. Without conversion, extension, or at least $5.00 million of new funding, default could raise the interest rate to 15% and permit holders to demand redemption at potentially more than the outstanding balance. The filing also disclosed possible $50,000 registration penalties if the underlying securities were not registered by November 25, 2011.
Key investor verification points
- Confirm the issuer identity: this filing is for Genesis Biopharma, Inc.; the request names Iovance Biotherapeutics, Inc.
- Verify whether the notes were converted, extended, repaid, or went into default, and whether any registration penalties arose.
- Check subsequent cash balances, financing raised, and the timing and amount of NIH and CRADA payments against the company’s short funding runway.
- Assess whether the NIH license, Cōntego development, and Lonza manufacturing arrangements progressed, and whether the company met applicable development milestones.
- Review potential dilution from the notes, warrants, options, share-based compensation, and planned equity financing.
- Evaluate the large reported losses in light of non-cash compensation, note discounts, and derivative fair-value movements; these items materially affect reported earnings and liabilities.